



### Postnatal management of Tetralogy of Fallot 1st year of life

#### **Damien Bonnet**

Unité médico-chirurgicale de Cardiologie Congénitale et Pédiatrique Hôpital Universitaire Necker Enfants malades - APHP, Université Paris Descartes, Sorbonne Paris Cité IcarP Cardiology, Institut Hospitalo-Universitaire IMAGINE

> Centre de Référence Maladies Rares Malformations Cardiaques Congénitales Complexes-M3C

> > Centre de Référence Maladies Rares

Maladies Cardiaques Héréditaires- CARDIOGEN



for rare or low prevalence complex diseases

Network (ERN GUARD-HEART)



for rare or low prevalence complex diseases

@ Network Respiratory Diseases (ERN-LUNG)


























# Prenatal diagnosis, pregnancy termination, perinatal and early neonatal mortality for selected (isolated) congenital heart anomalies

Paris Registry of Congenital Malformations, 1983-2010



ToF	83-88 %	89-94 %	95-00 %	00-10 %	p
Prenatal diagnosis	20.0	37.5	69.7	74	<0.005
Pregnancy termination	10.0	12.5	0	1.8	0.07
First week mortality	0	O	O	0.3	_
Perinatal mortality	0	7.1	2.9	2.0	0.63





# Recent studies show that prenatal diagnosis DOES NOT impact neonatal CHD mortality

Table 3 Association between prenatal diagnosis and risk of infant mortality for four specific congenital heart defects (CHDs), EPIdémiologie des CARDiopathies congénitales (EPICARD) Population-Based Cohort Study

	Prenatal diagnosis			Infant m	ortality	Risk ratio	95% CI
CHD	n*		n†	%	95% CI		
Functionally univentricular heart‡	No	7	3	42.9	9.9 to 81.6		
	Yes	32	17	53.1	34.7 to 70.9	1.2	0.5 to 3.1
d-Transposition of the great arteries‡	No	24	1	4.2	0.1 to 21.1		
	Yes	57	5	8.8	29 to 193	21	0.3 to 17.1
Tetralogy of Fallot‡	No	18	2	11.1	1.4 to 34.7		
	Yes	36	1	2.8	0.07 to 14.5	0.3	0.02 to 2.6
Coarctation of the aorta‡	No	44	3	6.8	1.4 to 18.7		
	Yes	29	2	6.9	0.8 to 22.8	1.0	0.2 to 5.7


<sup>&</sup>quot;N = number of live births (denominator data).

<sup>‡</sup>Cases with the specific International Paediatric and Congenital Cardiac Code for the given CHD; whether or not other CHD codes were also included, all cases with chromosomal or others anomalies were excluded.




<sup>†</sup>n= number of deaths (numerator data).

#### Impact of preterm birth on infant mortality for newborns with congenital heart defects The EPICARD Study Group




- •Preterm birth is associated with an approximately four-fold higher risk of infant mortality for newborns with CHD.
- •This excess risk appears to be mostly limited to newborns < 35 weeks of gestation and is disproportionately due to early deaths.



# One third of fetuses with ToF had extra cardiac anomalies 15% had intra-uterine growth retardation

### Death before hospital discharge in prenatally diagnosed « in-born » CCHD

Type of CHD/predicted physiology	Mortality before discharge n (%)		
at risk for Rashkind	8 (2.3)		
ductal-dependent pulmonary flow	13 (12.1)		
potentially ductal-dependent pulmonary flow	3 (2.1)		
ductal-dependent systemic flow	25 (39.6)		
potentially ductal-dependent systemic flow	16 (5.2)		
TAPVR	1 (12.5)		
AV block with CHD	0 (0)		
a priori at no risk of early intervention	7 (6.5)		
ALL	73 (6.7)		





## Prenatal diagnosis anticipates and prevents early demise Is in utero transfer a valid option?

# Common indications for in utero transfer

- Life threatening CHDs
  - Ex: TGA, TAPVR, HLHS
- Evolutive defects
  - Ex: Coarctation of the aorta
- Uncertain perinatal physiology
  - Ex: Tetralogy of Fallot
- Highly variable/unpredictable postnatal outcome
  - Ex: Ebstein

# Interventions in prenatally diagnosed « in-born » CHD 2543 in-born

#### **TGA**


748 in born
21% early demise
87% intervention

Suspected coarctation
486 in born
35% intervention

ToF
287 in born
4% intervention

### Is information on probability of complete repair individualized?


# Repair of TOF & PA-VSD at one year is closely related to size of pulmonary artery branches



3283 patients with simple TOF

Follow-up 18.5 years (maximum, 33 years; IQR, 14.6-22.4 years),


The median age at death was 1.0 years (IQR, 0.6-2.1 years), with range 3 days to 19.7 years.



3283 patients with simple TOF

Follow-up 18.5 years (maximum, 33 years; IQR, 14.6-22.4 years),


The median age at death was 1.0 years (IQR, 0.6-2.1 years), with range 3 days to 19.7 years.













#### Non modifiable factor: genetic condition



HR 3.64



# Perinatal strategy in simple ToF What is the plan during infancy?

ToF is a progressive disease with a potential increase in severity with time.

Optimizing the pulmonary blood flow in the most physiologic fashion may halt this process,


With the objective to normalize growth of the pulmonary arteries during infancy.

Thus, early repair is thought to be the optimal management approach.

Preserving the pulmonary valve predicts a better long-term outcome.

### Patients vs. Strategies & Alternative techniques







# Patients characteristics Different categories



#### Non modifiable

-underlying genetic conditions

#### Time-dependent

- -age and weight
- -symptoms


#### **Anatomical characteristics**

#### Non modifiable


- -location of the VSD
- -coronary artery anatomy

#### Time-dependent/modifiable

- -pulmonary valve and annulus
- -pulmonary artery branches (size, contiguity)
- -anatomy of the arterial duct







# Strategy Different options



**Goal:** closed VSD, preserved pulmonary valve without obstruction or regurgitation, normal growth of pulmonary artery branches, normal RV function, no aortic regurgitation

Make plan: elective repair or patient's dependent repair (staged or one step)

Get to work: when? and how?

Reach goal: initial strategy and long-term outcomes

### Alternative techniques



#### Palliate:

Blalock

or Stenting the arterial duct

or surgical right ventricle to pulmonary connection

or stenting the right outflow tract

#### Repair:


Trans-annular patch


Preserve pulmonary valve

**RV-PA** conduit

Limit right ventriculotomy

### Simple ToF(s) or one patient/one ToF





Outcomes of BT shunts

In hospital mortality (4-5%)

Inter-stage mortality (3.6%)

24% of acute post-operative events including shunt thrombosis, pulmonary overcirculation, shunt stenosis, and pulmonary artery stenosis

Hobbes B et al. Ann Thorac Surg 2017;104:1365-70


-vs. complete repair in neonatal period

### Stenting of arterial duct


#### 1-Patients characteristics

-Tendency for complex PDA-pulmonary artery morphology.










LPA coarctation

Tortuous

Underneath the aortic arch

From innominate artery Right aortic arch



### Surgical right ventricle to pulmonary connection

#### 1-Patients characteristics

- -small sized pulmonary arteries or LPA stenosis or disconnected PA
- -with very diminutive RVOT


#### 2-Strategy

- -promote symmetrical growth of PA
- -more physiological than shunt

#### 3-Alternative techniques

- -vs. stenting of the RVOT
- -vs. complete repair in neonatal period

#### Neonatal right ventricle to pulmonary connection



### Stenting of right ventricle outflow tract

#### 1-Patients characteristics

- -small sized pulmonary arteries
- -with very diminutive RVOT

#### 2-Strategy


- -promote symmetrical growth of PA
- -more physiological than shunt

#### 3-Alternative techniques


-vs. complete repair in neonatal period
























### Stenting of right ventricle outflow tract






IDEAL: elective repair > 3 months

**CATH**: Stenting

EARLY: repair before 3 months

Wilder TJ et al. JTCVS 2017 Sandoval JP et al. Circ Cardiovasc Interv 2016

### Stenting of right ventricle outflow tract vs. BT shunt



More reinterventions in stent
No mortality
Severe complications in 4-5%
No difference in late survival
Reduced ICU LOS
Better oxygenation?
Better growth of PA branches

### Non elective primary repair *vs.* shunt in infants < 3 months

BT patients were significantly younger (14 vs 25 days, P < .0001), had a higher incidence of extracardiac congenital abnormalities (41% vs 33%, P .02), had a higher rate of prematurity (17% vs 12%, P .04), and more frequently received PGE1


#### No difference in mortality between the two techniques

Irrespective of the surgical approach, younger patients (OR 1.03, P . 007), patients with noncardiac congenital anomalies (OR 2.48, P .016), and those with prematurity (OR3.28, P .007) had a higher risk of mortality.

# Initial strategy in Asymptomatic neonates with ToF Elective neonatal repair

### Metanalysis

3858 patients in 8 studies with 724 (19%) having undergone neonatal repair (6-20 days) and 3134 (81%) having undergone non-neonatal repair (60-220 days).



# Strategy in Asymptomatic infants > 3 months with ToF Elective repair

### Elective repair 6 kgs/3 months

#### 1-Patients characteristics


- -acceptable sized pulmonary arteries
- -pulmonary valve?
- -coronary artery epicardial course?
- -multiple VSD?

#### 2-Strategy


-limit late complications

#### 3-Alternative techniques


-None




# Outcomes ToF Parisian experience (07-17): 923 ToF (PA-VSD excluded)




### Can we have an algorithm in simple ToF?



### Can we have an algorithm in simple ToF?



### Can we have an algorithm in simple ToF?



#### Conclusion

ToF is a progressive disease with a potential increase in severity with time.

Repair in infancy is the common goal when feasible.

Elective repair before 3 months/5-6 kgs should not be preferred.

Non elective palliation should

- -be adapted to anatomy and patient's non-modifiable characteristics
- -optimize pulmonary blood flow in the most physiologic fashion
- -promote symmetric growth of pulmonary arteries
- -preserve long-term outcome

Tailored management is the optimal strategy

Local skills and preferences have an important role (are an important bias)







Helen Taussig

Alfred Blalock and Eileen Saxon

**Vivien Thomas**